



Webcast Alert: Aastrom Biosciences Announces Its Second Quarter Investor Conference Call

Ann Arbor, MI, February 6, 2006 -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast:

What: Aastrom Biosciences Second Quarter Fiscal Year End 2006 Investor Conference Call

When: Wednesday, February 8, 2006 @ 10:00 AM (EST)

Where: <http://www.vcall.com/IC/CEPage.asp?ID=100120>

How:

- For live over the **Internet** access, simply log on to the web at the address above.
- For **phone** access, interested parties should call toll-free (877) 407-9205 before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session.
- To download the **podcast**, simply log on to the web at the address above.

Contact: Kris Maly, Investor Relations Department, (734) 930-5777 or mail@aastrom.com

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.investorcalendar.com/> for 60 days. Through February 18, 2006, the audio replay of the call is available by dialing toll-free (877) 660-6853. When prompted on the phone, the Account # is 286, and the Conference ID# is 189683.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, are manufactured in the AastromReplicell[®] System, an industry-unique automated cell production system. Aastrom's TRC cell products are in clinical trials for the following therapeutic indications: severe bone fractures (U.S.: Phase I/II - multi-center; EU: Phase I/II - multi-center), ischemic vascular disease (EU: Phase I/II), jaw bone reconstruction (EU: proof of concept) and spine fusion (U.S.: Phase I/II - single-center). The Company has recently reported positive clinical trial results for its TRCs demonstrating both the clinical safety and ability of TRCs to induce healthy new tissue growth.

For more information, visit Aastrom's website at www.aastrom.com.

###